241 results match your criteria: "Erasmus Medical Center - Cancer Institute[Affiliation]"

Background: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease due to its aggressiveness, late-stage diagnosis, and limited treatment options. Microsatellite instability-high (MSI-H) cancers are susceptible to immune checkpoint inhibitors. Survival outcomes for patients with MSI-H PDAC are unknown as the disease is rare.

View Article and Find Full Text PDF

Purpose: Dynamic susceptibility contrast (DSC) MRI is commonly part of the clinical brain tumor imaging protocol. Usually, a preload of contrast agent is administered to minimize contrast-leakage T effects. However, recent studies have indicated that with adaptation of scan parameters (in particular, low flip angle), a preload is not required.

View Article and Find Full Text PDF
Article Synopsis
  • CDK4/6 inhibitors combined with endocrine therapy improve outcomes for patients with hormone-receptor positive, HER2-negative advanced breast cancer, but evidence comparing first-line and second-line use is limited.
  • The phase 3 SONIA trial involved 1,050 patients and showed no significant overall benefit for using CDK4/6 inhibitors first-line compared to second-line (31.0 vs. 26.8 months median progression-free survival).
  • Although first-line treatment led to longer duration of CDK4/6 therapy and more severe side effects, the quality of life was similar for both treatment timing, questioning the necessity for first-line CDK4/6 inhibitor usage in all cases.
View Article and Find Full Text PDF

Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis.

Lancet Planet Health

November 2024

Department of Hospital Pharmacy, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address:

Background: Hospitals contribute substantially to greenhouse gas emissions and face a moral obligation to prioritise emission reduction. Drugs constitute an important component of the greenhouse gas emissions of hospitals. Alternative dosing strategies (ADS) have been implemented to improve the cost-effectiveness of pembrolizumab and nivolumab.

View Article and Find Full Text PDF
Article Synopsis
  • Current research lacks clarity in distinguishing between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM), prompting a study of patient data spanning 1991 to 2023, which identified 71 NOM and 17 PON cases.
  • Analysis revealed that PON tumors are usually unilateral, often found in teratomas, while NOM are predominantly bilateral and not associated with teratomas.
  • The findings suggest a need for different treatment approaches; unilateral PON within teratomas should be treated as PON, while PON without teratoma components show similarities to midgut NET metastases, requiring thorough imaging to check for hidden midgut NET.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigated factors linked to positive sentinel lymph nodes (SLNs) in cT1-2N0 breast cancer patients who received neoadjuvant chemotherapy (NACT) and how this data might differ from patients who didn't receive NACT.
  • Out of 1,930 patients studied, 12.1% had positive SLNs, with specific tumor characteristics (like hormone receptor-positive status and lobular histology) significantly predicting this outcome.
  • The findings suggested low axillary recurrence rates in patients with positive SLNs, indicating that certain tumor features and older age could help identify individuals at higher risk for further disease after treatment.
View Article and Find Full Text PDF

(1) To describe ACPT implementation frequency in practice. (2) To assess associations of ACPT documentation with a) hospital care consumption, including systemic anti-tumor treatment in the last month(s) of life, and b) match between preferred and actual place of death, among oncology patients. A retrospective cohort study was performed.

View Article and Find Full Text PDF

Macrophage-mediated myelin recycling fuels brain cancer malignancy.

Cell

September 2024

Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands. Electronic address:

Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their cholesterol accumulation, are epigenetically rewired, display immunosuppressive features, and are enriched in the aggressive mesenchymal glioblastoma subtype.

View Article and Find Full Text PDF

In this study, we leveraged machine-learning tools by evaluating expression of genes of pharmacological relevance to standard-AML chemotherapy (ara-C/daunorubicin/etoposide) in a discovery-cohort of pediatric AML patients (N = 163; NCT00136084 ) and defined a 5-gene-drug resistance score (ADE-RS5) that was predictive of outcome (high MRD1 positivity p = 0.013; lower EFS p < 0.0001 and OS p < 0.

View Article and Find Full Text PDF

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.

Target Oncol

September 2024

Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Background: Atezolizumab is a programmed death-ligand 1 (PD-L1) checkpoint inhibitor for the treatment of different forms of cancer. The subcutaneous formulation of atezolizumab has recently received approval. However, treatment with atezolizumab continues to be expensive, and the number of patients needing treatment with this drug continues to increase.

View Article and Find Full Text PDF

Comparison of stereotactic radiotherapy and protons for uveal melanoma patients.

Phys Imaging Radiat Oncol

July 2024

Erasmus Medical Center Cancer Institute, University Medical Center, Department of Radiotherapy, Rotterdam, The Netherlands.

Article Synopsis
  • * The study analyzed data from 66 UM patients, assessing 14 different dose-volume parameters and evaluating four toxicity profiles, including visual impairment and radiation-induced conditions.
  • * Results indicated that proton therapy often had advantages in reducing toxicity risks compared to SRT, particularly for higher-stage tumors, although the choice of treatment may depend on individual risk priorities.
View Article and Find Full Text PDF

Background: Distinguishing postoperative fibrosis from isolated local recurrence (ILR) after resection of pancreatic ductal adenocarcinoma (PDAC) is challenging. A prognostic model that helps to identify patients at risk of ILR can assist clinicians when evaluating patients' postoperative imaging. This nationwide study aimed to develop a clinically applicable prognostic model for ILR after PDAC resection.

View Article and Find Full Text PDF

Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients.

Eur J Endocrinol

July 2024

ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Neuroendocrine tumors (NETs) are malignant neoplasms that can be associated with specific hormonal syndromes. We describe a novel syndrome of postmenopausal vaginal bleeding and ovarian estradiol overproduction due to ovarian NET localizations. An extensive workup was performed for 2 index patients with ovarian metastases of small bowel neuroendocrine tumors and symptoms of postmenopausal vaginal bleeding.

View Article and Find Full Text PDF

Background: For people with limited lifetime expectancy, the benefit of many medications may be outweighed by their potential harms. Despite the relevance of reducing unnecessary medication use, deprescribing is poorly enacted in primary care practice.

Aim: This study aims to describe factors, as identified by primary care professionals and patients, that influence deprescribing in the last phase of life.

View Article and Find Full Text PDF

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands.

Value Health

October 2024

Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Center for Health Economics Rotterdam (EsCHER), Erasmus University Rotterdam, Rotterdam, The Netherlands.

Objectives: Managed entry agreements and especially financial-based agreements are commonly used in European countries for innovative cancer pharmaceuticals. These agreements facilitate access to innovative treatments while mitigating financial risks for payers. This study focuses on the confidential price agreement made by the Dutch government for the reimbursement of pembrolizumab, the implications of broadening indications on cost-effectiveness, and the viability or desirability of said agreement.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with significant morbidity and mortality rates. AXIN1 is one of the top-mutated genes in HCC, but the mechanism by which AXIN1 mutations contribute to HCC development remains unclear.

Methods: In this study, we utilized CRISPR/Cas9 genome editing to repair AXIN1-truncated mutations in five HCC cell lines.

View Article and Find Full Text PDF

Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative).

Eur J Surg Oncol

July 2024

European Society of Surgical Oncology (ESSO), Education and Training Committee (ETC), Upper Gastrointestinal (UGI), Working Group (WG), Belgium; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; ESSO Past-President, Republic of Korea.

Article Synopsis
  • - Gastro-esophageal cancers (GECs) are serious illnesses with rapidly evolving management techniques, and the European Society of Surgical Oncology (ESSO) is focused on enhancing knowledge in this area through a multidisciplinary approach.
  • - The review covers various aspects of GEC management, including oligometastatic cancers, peritoneal metastases, Siewert Type II tumors, robotic surgery, and the use of molecular markers and immune therapies.
  • - The goal is to provide an updated overview of GEC management practices, highlight recent advancements, and promote discussions among surgical oncologists globally, benefiting both seasoned and training professionals in the field.
View Article and Find Full Text PDF

Background: Nested case-control (NCC) designs are efficient for developing and validating prediction models that use expensive or difficult-to-obtain predictors, especially when the outcome is rare. Previous research has focused on how to develop prediction models in this sampling design, but little attention has been given to model validation in this context. We therefore aimed to systematically characterize the key elements for the correct evaluation of the performance of prediction models in NCC data.

View Article and Find Full Text PDF

Purpose: Evidence suggests that proton-beam therapy (PBT) results in less toxicity and postoperative complications compared to photon-based radiotherapy in patients who receive chemoradiotherapy followed by esophagectomy for cancer. Ninety-day mortality (90DM) is an important measure of the postoperative (nononcologic) outcome as proxy of quality-of-care. We hypothesize that PBT could reduce 90DM compared to photon-based radiotherapy.

View Article and Find Full Text PDF

Purpose: The effectiveness of intensity-modulated proton therapy (IMPT) for esophageal cancer treated with definitive concurrent chemoradiation therapy remains inadequately explored. We investigated long-term outcomes and toxicity experienced by patients who received IMPT as part of definitive esophageal cancer treatment.

Patients And Methods: We retrospectively identified and analyzed 34 patients with locally advanced esophageal cancer who received IMPT with concurrent chemotherapy as a definitive treatment regimen at The University of Texas MD Anderson Cancer Center from 2011 to 2021.

View Article and Find Full Text PDF

Background: Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Normothermic catheter-based intraperitoneal chemotherapy and normothermic pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs compared to intravenous administration. We reviewed the effectiveness and safety of different methods of palliative intraperitoneal chemotherapy.

View Article and Find Full Text PDF

Objective: Despite lacking clinical data, the Dutch government is considering increasing the minimum annual surgical volume per center from twenty to fifty cytoreductive surgeries (CRS) for advanced-stage ovarian cancer (OC). This study aims to evaluate whether this increase is warranted.

Methods: This population-based study included all CRS for FIGO-stage IIB-IVB OC registered in eighteen Dutch hospitals between 2019 and 2022.

View Article and Find Full Text PDF